Pentoxifylline (PTX) selectively potentiates cyclosporine (CsA)-mediated suppression of cell-mediated lymphocytotoxicity: Median-effect analysis for the drug dose reductions in PTX and CsA combination treatment

Transplantation

Volumn 61, Issue 5, 1996, Pages 838-841

  Khabar, Khalid S A ^a,b   Dzimiri, Maud ^a   Parhar, Ranjit S ^a   Siddiqui, Shannaz ^a   Einspenner, Michael ^a   Al Humaidan, Abdelkarim ^a   Al Sediary, Sultan T ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b Dept of Biol and Medical Research ^*  (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; PENTOXIFYLLINE;

ARTICLE; CELLULAR IMMUNITY; DRUG POTENTIATION; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTOTOXICITY; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL;

CYCLOSPORINE; CYTOTOXICITY, IMMUNOLOGIC; DRUG SYNERGISM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS;

EID: 0029960830     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199603150-00029     Document Type: Article

References (12)

1. Bianco JA, Almgren J, Kern DL, et al. Evidence that oral pentoxifylline reverses acute renal dysfunction in bone marrow transplant recipients receiving amphotericin B and cyclosporine. Transplantation 1991; 51: 925.
2. Bianco JA, Appelbaum FR, Nemunaitis J, et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991; 78: 1205.
3. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, Larrick J. Cellular and molecular regulation of tumor necrosis factor production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230.
4. Tilg H, Eibl B, Pichl M, et al. Immune response modulation by pentoxifylline. Transplantation 1993; 56: 196.
5. Vincenti FG, Vasconcelos M, Birnbaum JL, et al. Pentoxifylline reduces the first-dose reactions following OKT3. Transplant Proc 1990; 25: 57.
6. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC, Rideout DC, eds. Synergism and antagonism in chemotherapy. New York: Academic Press, 1991: 61.
7. Khabar KSA, Siddiqui S, Armstrong JA. WEHI-13VAR: a stable and sensitive cell line for tumor necrosis factor activity. Immunol Lett 1995; 46: 107.
8. Chou J, Chou T-C. Dose effect analysis with microcomputers: quantitation of ED50, LD50, synergism, antagonism, low dose receptor binding and enzyme kinetics [IBM-PC series]. Cambridge, UK: Elsevier, 1988.
9. Beelen DW, Sayer HG, Franke M, et al. Constant intravenous pentoxifylline infusions in allogenic marrow transplant recipients: results of a dose escalation study. Bone Marrow Transplant 1993; 12: 363.
10. Khabar KSA, Armstrong, JA, Ho M. Analysis and examination of cytokine interactions by the median-effect model: an example with antiviral action of tumor necrosis factor and interferon-γ. J Interferon Res 1992; 12: 161.
11. Neuner P, Klosner G, Schauer E, et al. Pentoxifylline in vivo down-regulates the release of IL-1β, IL-6, IL-8 and tumor necrosis factor-α by human peripheral blood mononuclear cells. Immunology 1994; 83: 262.
12. Stockschlader M, Kalhs P, Peters S, et al. Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogenic bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 357.